Advertisement

  • More Choices to Treat Lung Cancer

    Advances in precision medicine and immunotherapy have led to better treatments for many patients with advanced lung cancer. But having a wider selection of therapies to choose from can make treatments more complex.

    by Kendall K. Morgan

  • Forward Look

    What’s Next

    A therapeutic vaccine targeting advanced cervical cancer.

    by Anna Azvolinsky

  • Worth the Wait

    Neoadjuvant therapy—using treatments such as chemotherapy, hormone therapy or radiation to shrink a tumor or treat unseen metastases before surgery—can improve outcomes for some patients.

    by Sharon Tregaskis

  • Facts and Stats

    Fall 2020

    vol 10 | issue 3
    The advent of checkpoint inhibitors has broadened the range of cancer patients able to take advantage of immunotherapy.

  • Targeted Therapy for Early-Stage Lung Cancer?

    A trial of the targeted therapy Tagrisso (osimertinib) for early-stage lung cancer finds that patients who take it go longer without having a cancer recurrence. Whether that should change clinical practice is under discussion.

    by Ashley P. Taylor

  • Support Grows for Making Transfusions a Part of Hospice

    Blood cancer patients have low rates of enrollment in hospice. One barrier to enrollment is that many hospices do not provide blood transfusions.

    by Jon Kelvey

  • In It for the Long Haul

    Doctors and researchers met online to discuss how the coronavirus pandemic changed cancer care in its early months, as well as how they can improve care and advocate for patients going forward.

    by Kate Yandell

  • From the Editor-In-Chief

    Measuring a Cancer Drug’s Effectiveness

    Surrogate endpoints can speed up drug approvals, but are they valid measures of effectiveness?

    by William G. Nelson, MD, PhD

  • Forward Look

    Cancer Treatments and Antioxidant Supplements Can Be a Bad Mix

    Christine Ambrosone on what her research shows.

    by Sue Rochman

  • Forward Look

    Here Come the Biosimilars

    As patents expire on biologic drugs, cancer patients get new options.

    by Stephen Ornes

Advertisement
Advertisement

From the AACR

  • A CAR-T Cell Therapy Pioneer

    In an interview, Carl June discusses CAR-T cell therapy, as well as his own experience with COVID-19.

  • Advances in Lymphoma

    A meeting on lymphoma covered diverse topics, ranging from immunotherapeutic strategies to advances in single-cell analyses to health disparities.

  • AACR COVID-19 and Cancer Meeting

    As COVID-19 spread, cancer researchers quickly mobilized to assess the effects the virus would have on cancer patients.

Advertisement

Video

Handle With Care

Advertisement

social media

donate to the AACR